Anticoagulation for neonates, infants and children

  • N. Schlegel
  • M. F. Hurtaud-Roux
  • F. Beaufils


Although rare in pediatric patients, thrombotic complications are observed since birth, with a first peak of frequency in the neonatal period and a second peak near the adolescence period.


International Normalize Ratio Activate Partial Thromboplastin Time Thrombotic Complication Heparin Therapy Protamine Sulphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adams M, Vegh P, Marzinotto V, Andrew M. Monitoring Coumadin therapy in children (personal communication).Google Scholar
  2. 2.
    Andrew M. An approach to the management of infants with impaired haemostasis. Baillière’s Clinical Haematology, 4, 251–289, 1991.PubMedCrossRefGoogle Scholar
  3. 3.
    Andrew M, Ofosu FA, Brooker L, Buchanan M. The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig. Thromb Res 56, 529–540, 1990.CrossRefGoogle Scholar
  4. 4.
    Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 12, 95–104, 1990.PubMedCrossRefGoogle Scholar
  5. 5.
    Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, POWERS P. Development of the human coagulation system in the healthy premature infant. Blood 72, 1651–1657, 1988.Google Scholar
  6. 6.
    Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. The development of the human coagulation system in the fullterm infant. Blood 70, 165–172, 1987.PubMedGoogle Scholar
  7. 7.
    Andrew M, Schmidt B. Use of heparin in newborn infants. Semin Thromb Haemostas 14, 28–32, 1988.CrossRefGoogle Scholar
  8. 8.
    Bagnall HA, Gomperts E, Atkinson JB. Continuous infusion of low-dose urokinase in the treatment of central venous catheter thrombosis, in infants and children. Pediatrics 83, 1963–1966, 1989.Google Scholar
  9. 9.
    Bosque E, Weaver L. Continuous versus intermittent heparin infusion of umbilical artery catheters in the newborn infant. J Pediatr 108, 141–143, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Bradley LM, Midgley FM, Watson DC, Getson PR, Scott LP 3d. Anticoagulant therapy in children with mechanical prosthetic cardiac valves. Am J Cardiol 56, 533–535, 1985.Google Scholar
  11. 11.
    De Boer-Van Den Berg M. Thèse, Maastricht March 13, 1987. (Professor H.C. Hemker).Google Scholar
  12. 12.
    Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 325, 1565–1568, 1991.PubMedCrossRefGoogle Scholar
  13. 13.
    Groupe D’Etudes Sur L’Hemostase Et La Thrombose. Utilisation des héparines en pratique médicale courante. STV 3, no 5(suppl), 4–10, 1991.Google Scholar
  14. 14.
    Guidelines on oral anticoagulation: second edition. British society for haematology. British committee for standards in haematology. Haemostasis and thrombosis task force. J Clin Pathol 43, 177–183, 1990.CrossRefGoogle Scholar
  15. 15.
    Harvey WH, Pick TE, Reed K, Solenberger RI. A prospective evaluation of the Port—a—Cath implantable venous access system in chronically ill adults and children. Surg Gynecol Obstet 169, 495–500, 1989.PubMedGoogle Scholar
  16. 16.
    Hirsch J, Poller L, Deykin D, Levine M, Dalen JE. Optimal therapeutic range for oral anticoagulants. Chest 95 no2 (suppl), 5S–11S, 1989. Google Scholar
  17. 17.
    Hockenberry MJ, Schultz WH, Bennett B, Bryant R, Falletta JM. Experience with minimal complications in implanted catheters in children. Am J Pediatr Hematol Oncol 11, 295–299, 1989.PubMedGoogle Scholar
  18. 18.
    Ino T, Benson LN, Freedom RM, Barker GA, Zipursky A, Rowe RD. Thrombolytic therapy for femoral artery thrombosis after pediatric cardiac catheterization. Am Heart J 115, 633–639, 1988.PubMedCrossRefGoogle Scholar
  19. 19.
    Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 95 no2 (suppl), 26S–36S, 1989. PubMedCrossRefGoogle Scholar
  20. 20.
    Loirat C, Pillion G, Schlegel N, Douenias R, Mathieu H. Etude des protéines de la coagulation et de la fibrinolyse au cours des Syndromes néphrotiques de l’enfant. Arch Fr Pediatr 36(suppl), LVI–LXIII, 1979. PubMedGoogle Scholar
  21. 21.
    Marlar RA, Broekmans AW, and the Working Party. Diagnosis and treatment of homozygous protein C deficiency. Report of the working party on homozygous protein C deficiency. The Subcommittee on protein C and protein S, International Committee on Thrombosis and Haemostasis. J Pediatr 114, 528–534, 1989. PubMedCrossRefGoogle Scholar
  22. 22.
    Matzch T, Berqvist D, Hedner U, Nilsson B, Ostergaard P. Effects of low molecular weight heparin on induction of osteopororis in rats. Thromb Haemost 63, 505–509, 1990.Google Scholar
  23. 23.
    Mc Donald MM, Hathaway WE. Anticoagulant therapy by continuous heparinization in newborn and older infants. J Pediatr 101, 451–457, 1982. CrossRefGoogle Scholar
  24. 24.
    Menache D. Replacement therapy in patients with hereditary antithrombin III Deficiency. Semin Haematol 28, 31–38, 1991.Google Scholar
  25. 25.
    Menache D, O’Malley JP, Schorr JB, Wagner B, Williams C, et al. Evaluation of the safety, recovery, half-life and clinical efficacy of Antithrombin III (Human) in patients with hereditary antithrombin III deficiency. Blood 75, 33–39, 1990.PubMedGoogle Scholar
  26. 26.
    Mirro J Jr, Rao BN, Strokes DC, Austin BA, Kumar M, Dahl GV, Colten M, Bala SL, Rafferty M, Hancock M et al. A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients. J Clin Oncol 7, 214–222, 1989.Google Scholar
  27. 27.
    Moore RA, Mc Nicholas KW, Naidech H, Flicker S, Gallagher JD. Clinically silent venous thrombosis following internal and external jugular central venous cannulation in pediatric cardiac patients. Anesthesiology 62, 640–643, 1985.Google Scholar
  28. 28.
    Rajani K, Goetzman BW, Wennberg RP, Turner E, Abilgaard C. Effect of heparinization of fluids infused through an umbilical artery catheter on catheter patency and frequency of complications. Pediatrics 63, 552–556, 1979.PubMedGoogle Scholar
  29. 29.
    Rao PS, Solymar L, Mardini MK, Fawzy ME, Guinn G. Anticoagulant therapy in children with prosthetic valves. Ann Thorac Surg 47, 589–592, 1989.PubMedCrossRefGoogle Scholar
  30. 30.
    Robin M, Boyer C Causes des thromboses veineuses de l’enfant et de 1’adolescent en dehors de la période neonatale. Arch Fr Pediatr 44, 467–472, 1987.PubMedGoogle Scholar
  31. 31.
    Schmidt B, Mitchell L, Ofosu FA, Andrew M. Standard assays understimate the concentration of heparin in neonatal plasma. J Lab Clin Med 112, 641–643, 1988.PubMedGoogle Scholar
  32. 32.
    Schmidt B, Ofosu FA, Mitchell L, Brooker LA, Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 25, 405–408, 1989.PubMedCrossRefGoogle Scholar
  33. 33.
    Shulman RJ, Rahman S, Mahoney D, Pokorny WJ, Bloss R. A totally implanted venous access system used in pediatric patients with cancer. J Clin Oncol 5, 137–140, 1987.PubMedGoogle Scholar
  34. 34.
    Smith S, Dawson S, Hennessey R, Andrew M. Maintenance of the patency of indwelling central venous catheters: is heparin necessary ? Am J Pediatr Hematol Oncol 13, 141–143, 1991.PubMedCrossRefGoogle Scholar
  35. 35.
    Stein PD, Kantrowitz A. Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest 95 no2 (suppl), 107S–117S, 1989. PubMedCrossRefGoogle Scholar
  36. 36.
    Stewart S, Cianciotta D, Alexson C, Manning J. The long-term risk of warfarin sodium therapy and the incidence of thromboembolism in children after prothetic cardiac valve replacement. J Thorac Cardiovasc Surg 93, 5S1–4, 1987. Google Scholar
  37. 37.
    Van Den Besselaar Amph. Scientific and standardization committee communication: recommended method for reporting therapeutic control of oral anticoagulant therapy. Thromb Haemost 63, 316–317, 1990.PubMedGoogle Scholar
  38. 38.
    Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 498–530, 1990. Google Scholar
  39. 39.
    Vieira A, Ofosu FA, Andrew M. Heparin sensitivity and resistance in the newborn: an explanation. Pediatr Res 25, 274–275, 1989.CrossRefGoogle Scholar
  40. 40.
    Wessel DL, Keane JF, Fellows KE, Robichaud H, Lock JE. Fibrinolytic therapy for femoral arterial thrombosis after cardiac catheterization in infants and children. Am J Cardiol 58, 347–351, 1986.PubMedCrossRefGoogle Scholar
  41. 41.
    Woods A, Vargas J, Berri G, Kreutzer G, Meschengieser S, Lazzari MA. Antithrombotic therapy in children and adolescents. Thromb Res 42, 289–301, 1986.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • N. Schlegel
  • M. F. Hurtaud-Roux
  • F. Beaufils

There are no affiliations available

Personalised recommendations